Gemina Laboratories Ltd. (GLABF)
USD 0.92
(17.08%)
USD 0.92
(17.08%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -5.21 Million CAD | 12.75% |
| 2023 | -5.97 Million CAD | -26.28% |
| 2022 | -4.73 Million CAD | -467.63% |
| 2021 | -834.15 Thousand CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -1.7 Million CAD | 12.64% |
| 2024 FY | -5.21 Million CAD | 12.75% |
| 2024 Q4 | -761.67 Thousand CAD | 34.79% |
| 2024 Q3 | -1.16 Million CAD | 25.98% |
| 2024 Q2 | -1.57 Million CAD | 7.65% |
| 2023 Q4 | -1.95 Million CAD | -56.29% |
| 2023 Q1 | -781.17 Thousand CAD | 40.26% |
| 2023 Q2 | -1.99 Million CAD | -154.77% |
| 2023 FY | -5.97 Million CAD | -26.28% |
| 2023 Q3 | -1.25 Million CAD | 37.11% |
| 2022 Q3 | -1.51 Million CAD | -97.86% |
| 2022 Q2 | -767.91 Thousand CAD | 32.94% |
| 2022 Q1 | -1.14 Million CAD | -28.01% |
| 2022 FY | -4.73 Million CAD | -467.63% |
| 2022 Q4 | -1.3 Million CAD | 13.94% |
| 2021 FY | -834.15 Thousand CAD | 0.0% |
| 2021 Q2 | -52.67 Thousand CAD | 0.0% |
| 2021 Q3 | -165.05 Thousand CAD | -213.36% |
| 2021 Q4 | -894.47 Thousand CAD | -441.93% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Capstone Therapeutics Corp. | -3.81 Million USD | -36.601% |
| Skye Bioscience, Inc. | -37.64 Million USD | 86.142% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 108.009% |
| Nascent Biotech, Inc. | -2.08 Million USD | -149.884% |
| Qrons Inc. | -789.34 Thousand USD | -560.899% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -1155.608% |
| Adynxx, Inc. | - USD | Infinity% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 25.291% |
| BioStem Technologies, Inc. | -8.48 Million USD | 38.503% |
| Regen BioPharma, Inc. | 1.02 Million USD | 609.697% |
| CSL Limited | 2.64 Billion USD | 100.197% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 91.666% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 109.847% |
| Rebus Holdings, Inc. | -1.02 Million USD | -411.45% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -290.645% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -724.91% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 67.131% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 93.041% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 20.671% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -1808.102% |
| SQZ Biotechnologies Company | -79.46 Million USD | 93.435% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -80.362% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -186.554% |
| Mesoblast Limited | -87.95 Million USD | 94.069% |
| Marizyme, Inc. | -65.34 Million USD | 92.017% |
| Genus plc | 7.9 Million USD | 166.035% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 52.103% |
| Pharming Group N.V. | -10.54 Million USD | 50.542% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -140.426% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -40.605% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 41.013% |
| ContraFect Corporation | -65.15 Million USD | 91.993% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -6.769% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -201.993% |
| IMV Inc. | -36.48 Million USD | 85.702% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 35.273% |
| MultiCell Technologies, Inc. | -380.07 USD | -1372486.366% |
| ONE Bio Corp. | 8.67 Million USD | 160.125% |
| Accustem Sciences Inc. | -3.74 Million USD | -39.247% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 89.908% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -311.7% |
| Q BioMed Inc. | -2.05 Million USD | -154.218% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -39.748% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -119.113% |
| Biomind Labs Inc. | -1.21 Million USD | -329.606% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 91.265% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -68.188% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 33.991% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -167.631% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -34734.328% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 10.322% |
| GB Sciences, Inc. | -1.36 Million USD | -283.115% |
| Alpha Cognition Inc. | -13.77 Million USD | 62.122% |
| HST Global, Inc. | -146.21 Thousand USD | -3468.011% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -197.292% |
| Halberd Corporation | -79.67 Thousand USD | -6447.504% |
| Enzolytics Inc. | -2.17 Million USD | -139.651% |
| Agentix Corp. | -1.37 Million USD | -279.621% |
| Resverlogix Corp. | -3.61 Million USD | -44.509% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -64.493% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 98.232% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 5423.254% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 175.337% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -31.306% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -72.391% |
| AVAX Technologies, Inc. | -6.41 Million USD | 18.661% |
| Zenith Capital Corp. | -10.59 Million USD | 50.766% |
| Genscript Biotech Corporation | -95.47 Million USD | 94.536% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -22345.525% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -25.829% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -8531.265% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -160.174% |
| Kadimastem Ltd | -3.3 Million USD | -57.731% |
| Helix BioMedix, Inc. | -1.05 Million USD | -393.987% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -1081.956% |
| LadRx Corporation | 400.44 Thousand USD | 1402.754% |
| Cell Source, Inc. | -5.32 Million USD | 1.962% |
| Regen BioPharma, Inc. | 1.02 Million USD | 609.697% |
| NovAccess Global Inc. | -4.76 Million USD | -9.385% |
| Affymax, Inc. | -14.42 Million USD | 63.833% |
| Itoco Inc. | -1.86 Million USD | -179.123% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -17.428% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -212.57% |
| Mobile Lads Corp. | -2.26 Million USD | -130.496% |
| CytoDyn Inc. | -49.84 Million USD | 89.533% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -6500.773% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -2186.792% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -454.076% |
| SYBLEU INC | -180.3 Thousand USD | -2793.33% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -223.474% |
| International Stem Cell Corporation | -131 Thousand USD | -3882.282% |
| Bioxytran, Inc. | -4.28 Million USD | -21.888% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -9512.303% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -106.177% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 89.148% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -146.773% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -568.059% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -64.671% |
| Neutra Corp. | -233.46 Thousand USD | -2134.506% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 74.29% |
| PureTech Health plc | -65.69 Million USD | 92.059% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 75.469% |
| IXICO plc | -1.17 Million USD | -342.851% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 47.448% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 90.868% |
| CSL Limited | 2.64 Billion USD | 100.197% |
| Cellectis S.A. | -103.17 Million USD | 94.944% |